Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...
In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
Stage 1 bladder cancer involves lamina propria invasion without detrusor involvement, requiring both eradication of index lesions and mitigation of field-change–driven multifocal recurrence risk.
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Bladder cancer is often overlooked, but a recent high-profile diagnosis is helping raise awareness. Football legend and Colorado head coach Deion Sanders recently revealed he had been diagnosed at age ...